NCT02137577

Brief Summary

The purpose of this study is to determine whether DEB is more effective than common PTA balloon using under in long-term vessel patency and inhibiting restenosis in the infrapopliteal artery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

11 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

May 5, 2014

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 14, 2014

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 17, 2020

Completed
Last Updated

June 18, 2021

Status Verified

June 1, 2021

Enrollment Period

4.5 years

First QC Date

May 5, 2014

Last Update Submit

June 17, 2021

Conditions

Keywords

drug eluting balloon catheter

Outcome Measures

Primary Outcomes (1)

  • Primary Patency [Time Frame: 6 months]

    Freedom from target vessel occlusion and clinically driven target lesion reintervention

    6 months

Secondary Outcomes (10)

  • device success rate

    during the operation(after using the DEB catheter)

  • technical success rates

    during the operation(after using the DEB catheter)

  • operation success rate

    during the operation(after using the DEB catheter)

  • if occured clinically driven TLR( target lesion revascularization)

    6 months, 12 months,18 months, 24 months

  • target lesion late lumen loss 6 months

    6 months

  • +5 more secondary outcomes

Study Arms (2)

DEB catheter

EXPERIMENTAL

use DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm

Procedure: DEB catheter

common PTA balloon catheter

ACTIVE COMPARATOR

use common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group

Procedure: common PTA balloon catheter

Interventions

DEB catheterPROCEDURE

DEB catheter (trade name: Litos/Tulip)

DEB catheter

common PTA balloon catheter

common PTA balloon catheter

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 85 years
  • Patients with peripheral artery disease (PAD), with Rutherford classification between 4 and 6
  • an occlusion or a minimum grade of stenosis Primary over 70% in the below popliteal artery
  • The expected survival time is more than 1 year
  • signed Patient informed consent form

You may not qualify if:

  • Serum creatinine clearance rate less than 30ml/min in patients
  • patients with acute thrombosis requiring lysis or thrombectomy
  • patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks
  • patient requiring intervention in both lower limbs at the same time
  • In-stent restenosis in the blow-knee popliteal artery
  • target lesion can't be cross by the guide wire
  • the stenosis rate of proximal outflow more than 30% with or without intervention
  • the length of the stenosis or occlusion in proximal outflow(including the Iliac artery, the superficial femoral artery, the Popliteal artery) more than 150mm before intervention
  • stenosis or occlusion of distal outflow for below-the-ankle artery.
  • expected major amputations at the index limb before intervention
  • known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc.
  • patients participating in another clinical trials with interfere with this trial in the same time
  • pregnancy and lactating woman
  • untreatable bleeding diatheses

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

People's Liberation Army General Hospital

Beijing, 100853, China

Location

Peking Union Medical College Hospital

Beijing, China

Location

Xiyuan Hospital, China Academy of Chinese Medical Sciences

Beijing, China

Location

Xuanwu Hospital, Capital Medical University

Beijing, China

Location

The First Affiliated Hospital of Dalian Medical University

Dalian, China

Location

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, China

Location

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Location

The Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Location

Shengjing Hospital of China Medical University

Shenyang, China

Location

The Second Hospital of Hebei Medical University

Shijiazhuang, China

Location

Tianjin Medical University General Hospital

Tianjin, China

Location

Related Publications (1)

  • Jia X, Zhuang B, Wang F, Gu Y, Zhang J, Lu X, Dai X, Liu Z, Bi W, Liu C, Wang S, Liistro F, Guo W. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of Infrapopliteal Artery Lesions (AcoArt II-BTK). J Endovasc Ther. 2021 Apr;28(2):215-221. doi: 10.1177/1526602820969681. Epub 2020 Oct 29.

MeSH Terms

Conditions

Peripheral Arterial Disease

Condition Hierarchy (Ancestors)

AtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular Diseases

Study Officials

  • Wei Guo

    Chinese PLA General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 5, 2014

First Posted

May 14, 2014

Study Start

May 1, 2014

Primary Completion

November 1, 2018

Study Completion

December 17, 2020

Last Updated

June 18, 2021

Record last verified: 2021-06

Locations